Navigation Links
UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis
Date:10/17/2009

imzia®, 1% placebo), rash (3% Cimzia®, 1% placebo), acute bronchitis (3% Cimzia®, 1% placebo), fatigue (3% Cimzia®, 1% placebo). Hypertensive adverse reactions were observed more frequently in patients receiving Cimzia® than in controls. These adverse reactions occurred more frequently among patients with a baseline history of hypertension and among patients receiving concomitant corticosteroids and non-steroidal anti-inflammatory drugs. Patients receiving Cimzia® 400mg as monotherapy every 4 weeks in RA controlled clinical trials had similar adverse reactions to those patients receiving Cimzia® 200mg every other week. The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 5% for Cimzia® and 2.5% for placebo.

Please see full prescribing information at www.cimzia.com/rheumatoidarthritis/pdf/Prescribing_Information.pdf

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing approximately 10,000 people in over 40 countries, UCB generated revenue of EUR 3.6 billion in 2008. UCB is listed on Euronext Brussels (symbol: UCB).

Forward-looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competi
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohns Patients
2. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
3. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
4. Tiny test tube experiment shows reaction of melting materials at the nano scale
5. New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations
6. Topical erectile dysfunction therapy shows promise
7. Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost
8. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
9. Video shows nanotube spins as it grows
10. MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
11. Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... the Institute for Molecular Medicine Finland (FIMM), University ... a novel "man and machine" decision support system ... was described in PLOS One scientific ... on computer vision algorithms similar to those used ... only the diagnostically most relevant areas. Tablet computers ...
(Date:8/21/2014)... , August 21, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... hormone therapy, is a means of replacing ... by the body. This type of therapy ...
(Date:8/21/2014)... 2014 The College of New Rochelle ... in the Mid-Hudson Region to be designated as a ... applications from qualified “high-technology” businesses that align with the ... to have been selected for the START-UP NY program ... to stimulate economic development in New York by growing ...
(Date:8/21/2014)... YORK , Aug. 21, 2014 ... congratulates Immune Pharmaceuticals Inc., a biotechnology company, on ... Market.  Immune previously traded on OTCQX®, the best ... by OTC Markets Group. Logo - ... Pharmaceuticals on the successful execution of its growth ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global ... April 26, 2012. Results press release will be ... 14:00 BST / 09:00 EDT, , Live ... and Graham Hetherington, Chief Financial Officer will host the investor and ...
... 12, 2012  The Orthopedic Design & Technology Forum will ... of Technology in Memphis, Tenn. Among the critical topics ... will address future trends in biologics—design implications, commercialism and ... the field of biologics: inductive proteins, conductive substrates, and ...
... Kan., April 11, 2012 Riordan Clinic ... Ronald Hunninghake have patented a new technology that may ... patients.  The research, recently published in the January/February issue ... "The Assessment of the Energy Metabolism in Patients with ...
Cached Biology Technology:Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012 2ODT Forum Presents Regenerative Technologies 2Riordan Clinic Research Institute Has Developed and Patented a Process for the Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome 2Riordan Clinic Research Institute Has Developed and Patented a Process for the Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome 3
(Date:8/21/2014)... geologist Juliane Mller the Fram Strait is a key region ... this passage between Greenland and Svalbard warm Atlantic water flows ... west side cold Arctic water masses and sea ice push ... A considerable portion of the Atlantic water cools here on ... The circulation of the water caused in this manner drives ...
(Date:8/21/2014)... designed by an international standards process, will be available ... an invited review published in the OnlineFirst version of ... the official journal of the American Society for Parenteral ... reduce the occurrence of misconnection that can be harmful ... are used to join medical devices, components, and accessories ...
(Date:8/21/2014)... in severe abdominal pain, vomiting and systemic inflammation. Every ... with the disease resulting in 1000 deaths. There is ... fluid and nutritional support. , Dr Jason Bruce, ... research, said "The major causes of pancreatitis include bile ... combined with a high fat diet. In fact, the ...
Breaking Biology News(10 mins):Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3New feeding tube connectors will improve patient safety 2Insulin offers new hope for the treatment of acute pancreatitis 2
... CA August 27, 2013 A recently reported ... injury could enable more timely therapeutic intervention in transplant ... As described by scientists at the University Medical Center ... new method uses Bio-Rad Laboratories, Droplet Digital PCR ...
... A team of scientists from the UCLA Departments of ... a three-year, $2 million grant from the W.M. Keck ... of donor livers. Dr. Jerzy W. Kupiec-Weglinski, principal ... Transplantation Research Center, said he hopes his research will ...
... member of a National Research Council (of the National Academies) ... is through Nov. 14, 2013. The task includes providing ... ocean surface following spills. Such guidelines are important for ... a notable voice in the investigation of the Exxon Valdez ...
Cached Biology News:Researchers develop rapid, cost-effective early detection method for organ transplant injury 2Researchers develop rapid, cost-effective early detection method for organ transplant injury 3UCLA scientists receive $2 million grant to improve quality of donor livers for transplant 2NJIT professor appointed to National Research Council 2
Custom LNA Oligonucleotide synthesis ,High quality Custom LNA Oligonucleotides are available for a variety of different specialty applications and innovative products. ,Please inquire for further...
... Plus is a chemiluminescent signal enhancing ... to boost the signal obtained with ... kits. ChemiLucent™ Plus is derived from ... conjugated complex- or chemiluminescent substrate enhancers, ...
... Multi-Disciplinary Team The Schleicher & ... stand-alone work center dedicated to custom ... The facilitys experienced project teams, comprised ... Marketing professionals, work closely with collaborators ...
... microRNA (miRNA) expression profiling service using Paraflo ... highly sensitive and specific direct detection of ... mature miRNA of all species available in ... database (Release 8.2). Our service is comprehensive ...
Biology Products: